| Current Price | $6.55 | Mkt Cap | $133.3M |
|---|---|---|---|
| Open | $6.80 | P/E Ratio | 0.00 |
| Prev. Close | $6.75 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $6.43 - $6.85 | Volume | 534,155 |
| 52-Wk Range | $4.01 - $48.80 | Avg. Daily Vol. | 18 |
A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.
| Current Price | $6.55 | Mkt Cap | $133.3M |
|---|---|---|---|
| Open | $6.80 | P/E Ratio | 0.00 |
| Prev. Close | $6.75 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $6.43 - $6.85 | Volume | 534,155 |
| 52-Wk Range | $4.01 - $48.80 | Avg. Daily Vol. | 18 |
The best Bull and Bear pitches based on recency and number of recommendations.
The company has two billion-dollar drugs in the pipeline.The first is a vaccine to combat RSV, the most common cause of bronchitis and pneumonia in babies. This is a multi-billion dollar drug. We are all waiting on phase 3 results.What made it a… More
Read the most recent pitches from players about NVAX.
Recs
FVelociraptor
(99.91)
Submitted: 7/26/2019 12:44:12 PM :
Start Price:
$4.35
NASDAQ:NVAX Score:
-51.67
https://velociraptor.cc
Recs
TMFGBudwell
(24.47)
Submitted: 1/2/2018 2:24:13 PM :
Start Price:
$1.28
NASDAQ:NVAX Score:
+400.51
RSV and flu vaccines
Recs
SaintCroix
(99.27)
Submitted: 11/24/2017 1:18:42 PM :
Start Price:
$1.39
NASDAQ:NVAX Score:
+339.74
The company has two billion-dollar drugs in the pipeline.
The first is a vaccine to combat RSV, the most common cause of bronchitis and pneumonia in babies. This is a multi-billion dollar drug. We are all waiting on phase 3 results.
What made it a buying opportunity is the stock getting hammered because of bad news in the phase 2 trials of the RSV drug. Same drug, but a different set of patients: old people.
The company's explanation for the bad news is that control group numbers for the disease was less than what the company was expecting. The efficacy was off because people in the control group didn't get sick, either.
Whether or not you buy that explanation--and I do--it's important to realize that young babies and very old people are two different classes of patients when it comes to RSV. That's why they're running two different trials, after all. So the idea that bad news in the phase 2 trial with old people means bad news for the phase 3 trial in babies isn't at all true.
Anyway, this stock has been a battle over the future of the RSV drug.
But what's making the stock take off now is drug #2.
Out of nowhere the company has had fantastic success with its NanoFlu drug. It's producing superior hemagglutinin antigen inhibition antibody responses (in ferrets) compared to Sanofi's flu vaccines. The numbers have been so impressive the company is rushing the drug into clinical trials. It is now in phase 1/phase 2. They could be filing for approval in 2019.
It's excitement over the flu vaccine--another multi-billion dollar market--that is making the stock jump right now.
Find the members with the highest scoring picks in NVAX.
Bigeric42 (99.94) Score: +1,216.19
The Score Leader is the player with the highest score across all their picks in NVAX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| Bigeric42 | 99.94 | 3/15/2019 |
|
1Y | $0.52 | +1,150.24% | +6.36% | +1,143.87 | 0 Comment | |
| TheAnamalous | 53.99 | 3/1/2019 |
|
5Y | $0.70 | +833.18% | +6.74% | +826.44 | 0 Comment | |
| stockcaps360 | < 20 | 8/1/2017 |
|
5Y | $1.06 | +517.92% | +20.56% | +497.36 | 0 Comment | |
| qqqaaazzz | < 20 | 8/1/2017 |
|
5Y | $1.06 | +517.92% | +20.56% | +497.36 | 0 Comment | |
| slingermoonsine | 76.43 | 5/15/2017 |
|
5Y | $1.07 | +512.15% | +24.30% | +487.85 | 0 Comment | |
| TMFGBudwell | 24.47 | 1/2/2018 |
|
1Y | $1.28 | +411.72% | +11.21% | +400.51 | 1 Comment | |
| bestiashow | 45.46 | 8/13/2018 |
|
5Y | $1.42 | +361.27% | +5.25% | +356.02 | 0 Comment | |
| stereotyp72 | 25.13 | 1/24/2017 |
|
5Y | $1.37 | +378.10% | +31.78% | +346.33 | 0 Comment | |
| isusan | < 20 | 1/9/2017 |
|
5Y | $1.39 | +371.22% | +31.48% | +339.74 | 0 Comment | |
|
SaintCroix | 99.27 |
|
|
5Y | $1.39 | +371.22% | +31.48% | +339.74 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
| Player Name | Player Rating |
Start Date |
Call | Time Frame |
Start Price |
Stock Gain |
S&P Gain |
Score | End Date | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| TrackJimCramer | 86.27 | 8/30/2016 |
|
3W | $6.96 | -5.89% | +36.85% | -42.74 | 0 Comment | |
| TrackJimCramer | 86.27 | 6/3/2016 |
|
3W | $6.12 | +13.73% | +3.67% | -10.05 | 8/30/2016 @ $6.96 | 0 Comment |
| TrackJimCramer | 86.27 | 8/12/2015 |
|
3W | $13.65 | -55.16% | +0.69% | -55.86 | 6/3/2016 @ $6.12 | 0 Comment |
| TrackJimCramer | 86.27 | 3/12/2015 |
|
3W | $9.29 | +46.93% | +0.84% | -46.10 | 8/12/2015 @ $13.65 | 0 Comment |
| TrackJimCramer | 86.27 | 1/15/2015 |
|
3W | $6.20 | +49.84% | +4.06% | +45.78 | 3/12/2015 @ $9.29 | 0 Comment |
| TrackUltraLong | < 20 | 4/29/2013 |
|
NS | $2.45 | +167.35% | +88.03% | -79.32 | 1 Comment | |
| TrackPoisedTo | < 20 | 7/13/2012 |
|
5Y | $2.03 | +222.66% | +122.87% | -99.79 | 0 Comment | |
| TrackWedbush | 88.24 | 3/15/2011 |
|
NS | $2.64 | +148.11% | +135.67% | +12.43 | 0 Comment | |
| TrackDawsonJames | < 20 | 6/16/2010 |
|
NS | $2.29 | +186.03% | +167.76% | +18.26 | 0 Comment | |
| TrackRothCapital | 59.62 | 3/15/2010 |
|
NS | $2.45 | -1.43% | +17.47% | -18.90 | 5/3/2011 @ $2.42 | 0 Comment |
| trackglobalhunte | < 20 | 12/3/2009 |
|
NS | $3.55 | +84.51% | +167.45% | -82.94 | 0 Comment | |
| TrackPiperJaff | 86.21 | 12/2/2009 |
|
NS | $3.14 | +108.60% | +168.97% | -60.37 | 0 Comment | |
| trackmerriman | 67.85 | 11/5/2009 |
|
NS | $3.92 | +67.09% | +182.36% | -115.27 | 0 Comment | |
| TrackOppenheimer | 20.09 | 10/31/2007 |
|
NS | $3.80 | +61.84% | -35.04% | +96.89 | 9/2/2009 @ $6.15 | 0 Comment |
| TrackJimCramer | 86.27 | 3/1/2006 |
|
3W | $5.69 | +8.96% | +53.49% | +44.53 | 1/15/2015 @ $6.20 | 0 Comment |
